Hong Kong · Delayed Price · Currency is HKD RemeGen Statistics
Total Valuation
RemeGen has a market cap or net worth of HKD 56.16 billion. The enterprise value is 55.42 billion.
| Market Cap | 56.16B |
| Enterprise Value | 55.42B |
Important Dates
The next estimated earnings date is Monday, August 17, 2026.
| Earnings Date | Aug 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RemeGen has 559.97 million shares outstanding. The number of shares has increased by 2.14% in one year.
| Current Share Class | 204.27M |
| Shares Outstanding | 559.97M |
| Shares Change (YoY) | +2.14% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 11.86% |
| Owned by Institutions (%) | 28.13% |
| Float | 344.69M |
Valuation Ratios
The trailing PE ratio is 26.57 and the forward PE ratio is 9.17. RemeGen's PEG ratio is 0.20.
| PE Ratio | 26.57 |
| Forward PE | 9.17 |
| PS Ratio | 14.61 |
| PB Ratio | 12.58 |
| P/TBV Ratio | 13.08 |
| P/FCF Ratio | 1,144.92 |
| P/OCF Ratio | 195.61 |
| PEG Ratio | 0.20 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 74.31, with an EV/FCF ratio of 1,129.83.
| EV / Earnings | 37.74 |
| EV / Sales | 14.42 |
| EV / EBITDA | 74.31 |
| EV / EBIT | 142.30 |
| EV / FCF | 1,129.83 |
Financial Position
The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.53.
| Current Ratio | 1.58 |
| Quick Ratio | 1.26 |
| Debt / Equity | 0.53 |
| Debt / EBITDA | 3.19 |
| Debt / FCF | 48.53 |
| Interest Coverage | 5.51 |
Financial Efficiency
Return on equity (ROE) is 45.33% and return on invested capital (ROIC) is 10.27%.
| Return on Equity (ROE) | 45.33% |
| Return on Assets (ROA) | 3.38% |
| Return on Invested Capital (ROIC) | 10.27% |
| Return on Capital Employed (ROCE) | 7.19% |
| Weighted Average Cost of Capital (WACC) | 6.47% |
| Revenue Per Employee | 1.26M |
| Profits Per Employee | 481,742 |
| Employee Count | 3,048 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 0.66 |
Taxes
In the past 12 months, RemeGen has paid 1.40 million in taxes.
| Income Tax | 1.40M |
| Effective Tax Rate | 0.10% |
Stock Price Statistics
The stock price has increased by +42.71% in the last 52 weeks. The beta is 0.43, so RemeGen's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | +42.71% |
| 50-Day Moving Average | 96.45 |
| 200-Day Moving Average | 90.61 |
| Relative Strength Index (RSI) | 23.67 |
| Average Volume (20 Days) | 3,821,727 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RemeGen had revenue of HKD 3.84 billion and earned 1.47 billion in profits. Earnings per share was 2.65.
| Revenue | 3.84B |
| Gross Profit | 3.34B |
| Operating Income | 389.47M |
| Pretax Income | 1.47B |
| Net Income | 1.47B |
| EBITDA | 680.56M |
| EBIT | 389.47M |
| Earnings Per Share (EPS) | 2.65 |
Balance Sheet
The company has 3.12 billion in cash and 2.38 billion in debt, with a net cash position of 739.92 million or 1.32 per share.
| Cash & Cash Equivalents | 3.12B |
| Total Debt | 2.38B |
| Net Cash | 739.92M |
| Net Cash Per Share | 1.32 |
| Equity (Book Value) | 4.47B |
| Book Value Per Share | 7.90 |
| Working Capital | 1.72B |
Cash Flow
In the last 12 months, operating cash flow was 287.11 million and capital expenditures -238.05 million, giving a free cash flow of 49.05 million.
| Operating Cash Flow | 287.11M |
| Capital Expenditures | -238.05M |
| Depreciation & Amortization | 296.06M |
| Net Borrowing | -472.73M |
| Free Cash Flow | 49.05M |
| FCF Per Share | 0.09 |
Margins
Gross margin is 86.86%, with operating and profit margins of 10.13% and 38.20%.
| Gross Margin | 86.86% |
| Operating Margin | 10.13% |
| Pretax Margin | 38.24% |
| Profit Margin | 38.20% |
| EBITDA Margin | 17.71% |
| EBIT Margin | 10.13% |
| FCF Margin | 1.28% |
Dividends & Yields
RemeGen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 4.72% |
| Buyback Yield | -2.14% |
| Shareholder Yield | -2.14% |
| Earnings Yield | 2.61% |
| FCF Yield | 0.09% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for RemeGen is 116.64, which is 65.45% higher than the current price. The consensus rating is "Buy".
| Price Target | 116.64 |
| Price Target Difference | 65.45% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | 22.95% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RemeGen has an Altman Z-Score of 7.75 and a Piotroski F-Score of 7.
| Altman Z-Score | 7.75 |
| Piotroski F-Score | 7 |